Is the Wegovy price going down in the UK?

What official sources and market data tell us about Wegovy's UK price

NICE recommended semaglutide (Wegovy) for weight management under specific clinical criteria in March 2023, making it the first GLP-1 medicine to receive formal NHS approval for obesity in adults, you can read the full NICE technology appraisal TA875 for the exact eligibility thresholds. NHS access, however, remains limited to specialist weight management services with long waiting lists, which has kept private demand consistently high. High demand rarely produces falling prices.

On the private market, providers set their own rates. Typical private prices for Wegovy in the UK currently range roughly £149 to £375 a month depending on dose and provider, as widely reported through 2025 into 2026. These figures are not fixed, they reflect the cost of the medicine to the pharmacy, clinical overheads, and the service wrapped around the prescription. Nothing in Novo Nordisk's publicly available communications points to an imminent list-price cut. Our Wegovy pricing overview keeps a factual summary of the current landscape if you want more detail on what shapes those numbers.

The MHRA-approved 7.2mg single-dose pen, confirmed on 14 April 2026, gave patients a higher-dose option, but new formulations tend to enter at a premium, not a discount. If you're wondering whether Wegovy prices are going up rather than staying flat, the evidence we've gathered suggests the direction of travel is not straightforwardly downward. Whether the price of Wegovy goes down in any meaningful way over the next year remains genuinely uncertain.

The factors that could push Wegovy prices lower, and the ones pulling the other way

Several things could, in principle, reduce private prices over time. Patent expiry is the biggest structural lever: once biosimilar semaglutide enters the market, competition typically depresses costs significantly. That is likely still some years away for the UK. Improved manufacturing capacity at Novo Nordisk (which has invested heavily in production) could ease supply constraints and reduce cost pressure on pharmacies. A broader NHS rollout might also reduce private demand, though the TA875 criteria remain restrictive, and NHS waiting times are a practical barrier for many people.

Pulling in the other direction: sustained consumer demand, the cost of clinical infrastructure that legitimate pharmacies must maintain (ID checks, live weight verification, prescriber review), and the simple economics of a market where the medicine remains in short supply relative to the number of people who meet prescribing criteria. If you're asking whether Wegovy is coming down in price, checking reputable UK health-news sources alongside Novo Nordisk's own announcements takes under a minute and is a better guide than social-media speculation. For a closer look at whether costs have been rising rather than falling, our piece on whether Wegovy prices are going up covers that evidence too.

What headline prices often leave out, and what a single transparent price actually means

When comparing prices, the figure advertised is rarely the total. Some providers charge separately for the initial consultation, the prescription, delivery, and any follow-up clinical support. A price that looks lower at first glance can end up costing more once those elements are added back in, or it can mean less clinical oversight, which matters for a medicine that requires dose titration and ongoing monitoring.

At nume, we are deliberately not the cheapest option in the market. That is a choice, not an oversight. One price covers the consultation, the prescription, the medicine, next-working-day tracked delivery, and 7-day aftercare from our clinical team. There are no add-on fees and no subscription: every repeat order gets a fresh clinical review. Our team and approach are built around that model. If you'd like to see what that looks like in practice, our prescribers (including our lead clinician) are available to answer questions through aftercare.

For a full breakdown of what a month's treatment involves financially, our Wegovy monthly cost page sets it out plainly, without the small print.

Why 'cheapest' is the wrong question to ask about a prescription medicine

For any prescription-only medicine, the lowest price available online is not the safest metric. The MHRA has documented seizures of counterfeit weight-loss pens sold through unverified online channels, including fake pens that contained insulin rather than semaglutide. Sellers offering these medicines without proper clinical assessment are a safety risk, not a bargain. The MHRA's Yellow Card scheme accepts reports of suspected counterfeit medicines as well as side effects, worth knowing if you ever encounter a seller whose pricing or process seems implausible.

The questions that do more useful work: is the pharmacy registered on the GPhC register? Does the service require a genuine clinical consultation? Is the supply chain licensed in the UK? You can check any online pharmacy's registration in seconds at the GPhC register, nume's premises registration number is 9012878. A small saving is not the measure that keeps you safe on a treatment that requires titration, monitoring and a clinician's judgement. For those still wondering whether the cost of Wegovy is going down, those fundamentals stay constant regardless of where prices move. Check your eligibility with our clinical team and see what a properly supervised prescription actually involves.